About Isogenica limited
Isogenica Limited: Revolutionizing the Future of Biotherapeutics
Isogenica Limited is a leading biotechnology company that specializes in developing highly versatile small format antibodies for the construction of next-generation biotherapeutics. The company has been at the forefront of innovation in the field of antibody engineering, and its cutting-edge technology has enabled it to create novel therapeutic solutions for some of the most serious diseases.
Founded in 2000, Isogenica has established itself as a pioneer in the development of synthetic antibody libraries. Its proprietary CIS display technology allows for rapid screening and selection of high-affinity binders against virtually any target, making it an ideal platform for drug discovery and development.
The company's expertise lies in creating fully human antibodies that are smaller than traditional monoclonal antibodies. These small format antibodies have several advantages over their larger counterparts, including improved tissue penetration, faster clearance from circulation, and reduced immunogenicity. This makes them ideal candidates for use as therapeutics against a wide range of diseases.
Isogenica's innovative approach to antibody engineering has led to several successful collaborations with pharmaceutical companies around the world. Its partners include some of the biggest names in biotech such as AstraZeneca, Boehringer Ingelheim, and MSD Animal Health.
One area where Isogenica is making significant strides is cancer therapy. The company's small format antibodies have shown promising results in preclinical studies against various types of cancer including breast cancer, lung cancer, and pancreatic cancer. By targeting specific tumor antigens with high precision and efficacy while minimizing off-target effects on healthy cells or tissues - these new biotherapeutic agents hold great promise for improving patient outcomes.
Another area where Isogenica is making significant contributions is infectious disease research. The COVID-19 pandemic highlighted how important it is to develop effective treatments quickly when faced with emerging viral threats - something that Isogenica was able to do by leveraging its expertise in antibody engineering. The company has developed a range of small format antibodies that can neutralize SARS-CoV-2, the virus responsible for COVID-19, and is currently working with partners to advance these candidates into clinical trials.
Isogenica's commitment to innovation and excellence has earned it several accolades over the years. In 2019, the company was awarded the prestigious Queen's Award for Enterprise in Innovation - a testament to its contribution to advancing science and technology in the UK.
In conclusion, Isogenica Limited is a biotechnology company that is revolutionizing the future of biotherapeutics. Its cutting-edge technology and expertise in antibody engineering have enabled it to create novel therapeutic solutions for some of the most serious diseases. With its focus on cancer therapy and infectious disease research, Isogenica is poised to make significant contributions towards improving patient outcomes worldwide.